US 9404127

I'll search for authoritative information on US 9,404,127 and any associated litigation/docket activity.

Let me check for any 2025–2026 docket activity, including the Acuitas declaratory-judgment case and any further appellate proceedings.

Let me verify the full claim set (independent claims) and the 2026 litigation/CAFC status.

US Patent 9,404,127 — Analyst Summary

⚠️ Status alert up front: This patent is not a live enforcement asset. All of its claims (1–22) were held unpatentable in an IPR and the Federal Circuit affirmed. There is no 2026 CAFC docket activity on the '127 patent. Separately, Arbutus and Moderna reached a settlement in the related LNP litigation in 2026, but that settlement concerns other patents — not the '127 patent.

1. Bibliographic data (as confirmed by USPTO/CAFC records)

Note on the "expiration" discrepancy: the anticipated expiration is June 30, 2031, yet the Google Patents record I fetched shows "Expired – Fee Related." I cannot fully reconcile these from the material available; I flag it rather than assert one over the other.

2. Abstract (verbatim, per USPTO copy of the patent)

"The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP."

3. Independent claims — plain-language overview

The '127 patent has claims 1–22, with a single independent claim (claim 1). In its IPR petition, Moderna's briefing expressly refers to "the sole independent claim," and both the PTAB and Federal Circuit treat claim 1 as the representative claim. I did not locate a second independent claim; I flag this as a point of residual uncertainty since I do not have a verbatim granted-claims listing in front of me.

Claim 1 (the only independent claim) — plain language:
A composition made up of many nucleic acid–lipid particles (a "plurality"), where each particle contains four things:

• (a) a nucleic acid (e.g., an siRNA or mRNA payload);
• (b) a cationic lipid;
• (c) a non-cationic lipid; and
• (d) a conjugated lipid that inhibits particle aggregation (e.g., a PEG-lipid),

characterized by the structural limitation that at least about 95% of the particles have a "non-lamellar morphology" — i.e., a non-bilayer three-dimensional structure (for example, an inverse hexagonal (H_II) or cubic phase) rather than stacked lipid bilayers.

That last clause is the celebrated "Morphology Limitation," and it is the clause on which the patent ultimately died (see §5).

Note the drafting feature that mattered: claim 1 as granted recites the lipid components without the mol % ranges emphasized in the specification. Those numerical ranges (e.g., cationic lipid ~50–85 mol %; non-cationic lipid ~13–49.5 mol %; conjugated lipid ~0.5–10 mol %) appear in the written description and in dependent claims (claims 10–12 per the Federal Circuit's opinion), not in claim 1.

Dependent claims (themes), per the PTAB/CAFC record:

• Claim 3 — nucleic acid is mRNA;
• Claim 8 — nucleic acid is fully encapsulated;
• Claim 9 — the non-lamellar particle has a specific three-dimensional structure (inverse hexagonal / cubic);
• Claims 10–12 — % ranges of the lipid components;
• Others per the specification's SNALP embodiments (e.g., the "1:57," "1:62," "7:54," and "7:58" formulations).

I do not have the verbatim text of each dependent claim, so the above is a theme-level summary rather than a claim-by-claim quotation.

4. What the invention is actually about (context)

The specification describes stable nucleic acid-lipid particles (SNALPs) prepared by either a Stepwise Dilution Method (SDM) or a Direct Dilution Method (DDM). The asserted "surprising discovery" was that controlling (i) the lipid composition and (ii) the formation process yields particles with a non-bilayer, non-lamellar morphology that show enhanced gene-silencing activity. Morphology was characterized by Cryo-TEM (and/or DSC, X-ray diffraction) using the particle images in FIGS. 3–12. Exemplary payloads include anti-ApoB and anti-PLK-1 siRNAs; the specification also contemplates cholesterol/phospholipid non-cationic lipids and PEG-DAA conjugates.

5. Post-grant proceedings and current legal status

IPR2018-00680 — Moderna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc.

• Petition filed Feb. 2018 (Moderna's first challenge to Arbutus LNP patents); instituted Sept. 12, 2018.
• Grounds included §102/§103 over US 8,058,069 (the '069 patent) — itself an Arbutus patent sharing three of the same inventors — as well as the '817 publication, the '099 patent, Koltover, and Ewert.
• Final Written Decision, Sept. 10, 2019: all of claims 1–22 unpatentable as inherently anticipated by the '069 patent. The Board found the morphology limitation, though not expressly disclosed, was an inherent property of the same formulations made by the same disclosed processes.
• https://portal.unifiedpatents.com/ptab/case/IPR2018-00680

Federal Circuit — Arbutus Biopharma Corp. v. ModernaTX, Inc., No. 2020-1183 (Apr. 11, 2023)

• The court affirmed, holding substantial evidence supported inherent anticipation. Because the '127 and '069 patents disclose "the same or essentially the same" formulations and processes (a "limited number" of five formulations and two processes), following the '069 disclosure would "naturally result in a composition having the claimed morphological property."
• The opinion is also a notable incorporation-by-reference case: the '031 publication and the '025 publication incorporated into the '127 patent (to describe DDM and SDM, respectively) were treated as effectively part of the host documents.
• Decision PDF: https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/12/PTAB-IPR2018-00680-Appeal-Decision.pdf
• Commentary: https://www.finnegan.com/en/insights/blogs/at-the-ptab-blog/ripples-of-incorporation-by-reference-lead-to-cancellation-of-arbutus-biopharmas-claims.html

2026 checkpoint on "CAFC dockets": I found no 2026 Federal Circuit docket activity on the '127 patent. The controlling appellate decision remains 2020-1183. A cert petition to the Supreme Court is a theoretical possibility, but I found no evidence of one and will not assert one.

Related district-court matters listing the '127 patent:

• Acuitas Therapeutics Inc. v. Genevant Sciences GmbH et al., S.D.N.Y. No. 1:22-cv-02229 (filed Mar. 18, 2022) — Acuitas DJ action naming nine Arbutus/Genevant patents including the '127 patent; terminated Aug. 7, 2023.
• Acuitas Therapeutics Inc. v. Genevant Sciences GmbH et al., D.N.J. No. 3:23-cv-04200 (filed Aug. 4, 2023).
• Arbutus Biopharma Corp. v. Moderna, Inc., D. Del. No. 1:22-cv-00252 (filed Feb. 28, 2022). Critically, the '127 patent was not asserted here — Arbutus asserted US 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378.

2026 commercial development (other patents only): A March 12, 2026 article reports that Arbutus and Genevant settled their LNP litigation with Moderna, involving an immediate July 2026 payment of $950 million plus a further $1.3 billion subject to an appeal concerning whether the U.S. federal government should bear the cost (COVID-19 vaccine procurement). That settlement concerns the separately-asserted LNP patents — not the '127 patent, whose claims were already cancelled. Source: https://www.mbhb.com/intelligence/snippets/quo-vadis-mrna-vaccine-technology-the-state-of-the-ip-lawsuits/ (the article renders the vaccine name in a form I read as "Spikemax®"; I am reporting the source text rather than correcting it.)

6. Uncertainty disclosures

• Independent-claim count: I am confident claim 1 is independent and is the sole independent claim based on Moderna's own petition language ("the sole independent claim") and the PTAB/CAFC framing, but I have not personally verified a verbatim granted-claims listing. Treat the dependent-claim themes in §3 as a summary, not a quotation.
• Legal status field: Google Patents shows "Expired – Fee Related" while also listing a 2031 anticipated expiration. Both are reported above without resolution.
• Assignee chain: Multiple "reassignment" events appear in the record (2016 assignments to Protiva, a 2016 corrective assignment, and a 2018 merger into Arbutus Biopharma Corporation). The current owner is Arbutus Biopharma Corp.
• I did not find any authoritative source indicating the '127 patent is currently asserted in any pending litigation.

I'll search for litigation involving US 9,404,127 specifically.

Let me search for the specific district court and CAFC cases.

Let me verify the Delaware case and which patents were asserted in the Acuitas declaratory judgment action.

Litigation involving U.S. Patent No. 9,404,127 ("the '127 patent")

Important framing note first. The '127 patent (filed Mar. 9, 2015; issued Aug. 2, 2016; priority June 30, 2010; assignee Arbutus Biopharma Corp., originally Protiva Biotherapeutics, Inc.) was never asserted as a patent‑in‑suit in any infringement action. It was challenged at the PTAB by Moderna and cancelled. So the "litigation" here is (a) the IPR/appeal that invalidated it, plus (b) related proceedings that the Google Patents "family has litigation" flag attaches at the family level but that do not actually assert the '127 patent. I flag that distinction explicitly so you don't over‑read the Google Patents litigation links.

A. Proceedings directly involving the '127 patent

1. IPR2018‑00680 — Moderna Therapeutics, Inc. v. Arbutus Biopharma Corp. (originally named Protiva Biotherapeutics, Inc.)

• Forum: U.S. Patent Trial and Appeal Board (PTAB)
• Case number: IPR2018‑00680
• Petitioner: Moderna Therapeutics, Inc.
• Patent owner: Arbutus Biopharma Corp. / Protiva Biotherapeutics, Inc.
• Filed: February 21, 2018
• Instituted: September 12, 2018
• Claims challenged: 1–22 (all claims)
• Ground: Anticipation under §102 by U.S. Patent No. 8,058,069 (the '069 patent), an earlier Arbutus/Protiva patent — including the "Morphology Limitation" (at least about 95% of particles having a non‑lamellar morphology) as an inherent property of the disclosed formulations.
• Final Written Decision: September 10, 2019 — all claims 1–22 held unpatentable (invalid) as inherently anticipated.
• Status: Closed in favor of Petitioner (Moderna). PTAB panel: APJs Richard James Smith (author), Sheridan K. Snedden, and (per one docket source) Den Serna / David C. McKone, Frederick C. Laney, Karl D. Easthom appear in aggregate‑statistics listings.
• Source: Google Patents family litigation link (https://portal.unifiedpatents.com/ptab/case/IPR2018-00680); Patexia (https://services.patexia.com/lawsuits/Moderna-Therapeutics-Inc-v-Arbutus-Biopharma-Corporation-et-al-id-[111723](/patent/111723)); Ex Parte PTAB (https://ai-lab.exparte.com/case/ptab/IPR2018-00680/moderna-therapeutics-inc-v-arbutus-biopharma-corp).

2. CAFC No. 2020‑1183 — Protiva Biotherapeutics, Inc. (Arbutus Biopharma Corp.) v. Moderna Therapeutics, Inc. (ModernaTX, Inc.)

• Forum: U.S. Court of Appeals for the Federal Circuit
• Appeal number: 20‑1183
• Appellant: Protiva Biotherapeutics, Inc. (amalgamated into Arbutus Biopharma Corp.)
• Appellee: Moderna Therapeutics, Inc. / ModernaTX, Inc.
• Docketed: November 27, 2019 (notice of appeal; a "Constitutional Challenge to Federal Statute" notice was filed the same day)
• Oral argument audio posted: posted on the CAFC site (dated November 4, 2022)
• Decision: April 11, 2023 — Affirmed the PTAB; the Federal Circuit held the Board did not err in finding the Morphology Limitation inherently anticipated, and that the incorporated references in the '069 patent are "effectively part of the [host document] as if they were explicitly contained therein." All claims of the '127 patent were thereby cancelled.
• Status: Concluded; Arbutus lost. No further review is reported in the sources I found (the Chinese‑language practitioner summaries note a theoretical cert. possibility but no Supreme Court case is identified).
• Sources: CAFC case page (https://www.cafc.uscourts.gov/11-04-2022-2020-1183-arbutus-biopharma-corporation-v-modernatx-inc-audio-uploaded/); Justia docket (https://dockets.justia.com/docket/circuit-courts/cafc/20-1183); Finnegan client alert (https://www.finnegan.com/en/insights/blogs/at-the-ptab-blog/ripples-of-incorporation-by-reference-lead-to-cancellation-of-arbutus-biopharmas-claims.html); Reuters coverage (Blake Brittain, Apr. 11, 2023).

Practical result: the '127 patent's term is shown on Google Patents as anticipated expiration 2031‑06‑30, but all claims stand cancelled following the FWD and the 2023 affirmance.

B. Family‑level litigation that does NOT assert the '127 patent (flagging to prevent mis‑attribution)

The Google Patents page for US 9,404,127 displays three litigation/PTAB links because they attach to the patent family (WO2012/000104; US 9,006,417; US 9,518,272; etc.), not because the '127 patent was asserted. Two are worth identifying precisely:

3. S.D.N.Y. No. 1:22‑cv‑02229 — Acuitas Therapeutics Inc. v. Genevant Sciences GmbH and Arbutus Biopharma Corp.

• Forum: U.S. District Court for the Southern District of New York
• Case number: 1:22‑cv‑02229 (‑ER / ‑MKV; assigned to Judge Edgardo Ramos, later Judge Mary Kay Vyskocil)
• Plaintiff: Acuitas Therapeutics Inc.
• Defendants: Genevant Sciences GmbH; Arbutus Biopharma Corp.
• Filed: March 18, 2022
• Nature: Declaratory‑judgment action (N.O.S. 830) seeking declarations that Pfizer/BioNTech's COMIRNATY® does not infringe and that nine Arbutus patents licensed to Genevant are invalid. The nine asserted/identified patents are described in the pleadings and coverage as Arbutus patents said to cover COMIRNATY® (the '069, '359, '668, '435, '651, '378 family members would be the candidates). I could not confirm from the sources retrieved that the '127 patent was one of the nine — and because the '127 patent had already been invalidated by the 2019 FWD (then on appeal), it is plausible it was omitted. Treat the '127‑specific link as unverified.
• Outcome/Status: Voluntarily dismissed without prejudice and without costs by Acuitas under Rule 41(a)(1)(A)(i) on August 4, 2023; docket terminated August 7, 2023. Related Acuitas activity shifted to a later New Jersey declaratory‑judgment action (D.N.J. No. 3:23‑cv‑04200) against Arbutus and Genevant.
• Sources: CourtListener docket 63169706 (https://www.courtlistener.com/docket/63169706/acuitas-therapeutics-inc-v-genevant-sciences-gmbh/); Docket Alarm documents 36, 44, 48, 79; Law.com Radar.

4. D. Del. No. 1:22‑cv‑00252 — Arbutus Biopharma Corp. and Genevant Sciences GmbH v. Moderna, Inc. and ModernaTX, Inc.

• Forum: U.S. District Court for the District of Delaware (C.A. No. 22‑252‑MSG / later ‑JDW; Judge Mitchell S. Goldberg)
• Filed: February 28, 2022
• Asserted patents: U.S. Patent Nos. 8,058,069; 8,492,359; 8,822,668; 9,364,435; 9,504,651; and 11,141,378 — the '127 patent is not asserted. (Reuters noted Arbutus's suits "do not include the canceled patent.")
• Accused product: Moderna's mRNA‑1273 (Spikevax) COVID‑19 vaccine.
• Status as of the sources retrieved: Claim construction issued April 3, 2024 (favorable to Arbutus on several terms). Summary judgment/Daubert phase from July 2025; trial set for Sept. 24, 2025, then March 2026. A Feb. 2, 2026 decision (No. 1:22‑cv‑00252‑JDW) largely denied Moderna's §1498(a) government‑use transfer motion, applied prosecution‑history estoppel to bar doctrine‑of‑equivalents for the molar‑ratio patents, and left indefiniteness for the jury. Arbutus has since reported a March 2026 settlement agreement with Moderna resolving its global LNP litigation (announced July 15/16, 2026, with a ~$178M payment to Arbutus).
• Sources: Vitallaw IP Law Daily (Feb. 3, 2026); CourtListener dockets; Arbutus investor releases (https://investor.arbutusbio.com/...).

Related (not '127): Arbutus/Genevant v. Pfizer/BioNTech in D.N.J. (filed Apr. 4, 2023), plus 2026 international actions (Canada T‑3200‑26; UPC PR‑UPC‑CFI‑0002562/2026 and 0002566/2026) asserting different patents (e.g., Canadian Pat. 2,721,333; EP 4 241 247 / EP 4 495 237) — none asserts US 9,404,127.

C. Summary table

Caveats

• The '127 patent's only direct litigation is the Moderna IPR and its Federal Circuit appeal; both ended adversely to Arbutus.
• Whether the '127 patent was among the nine patents in Acuitas v. Genevant (S.D.N.Y.) is not confirmed in the sources I retrieved; I am not asserting it was.
• No affirmative infringement action asserting the '127 patent is known to me. If one exists, it is not reflected in the sources searched.
• I searched Unified Patents' litigation portal references (via the Google Patents links), PTAB/Patexia, CourtListener/RECAP, Justia, CAFC, and news coverage. I was unable to open the Unified Patents portal pages directly to double‑check their entries.

I'll start by verifying the one PTAB proceeding that the patent's own Google Patents page flags (IPR2018-00680), then check for any others.

Good — one proceeding is confirmed. Now let me pin down the CAFC appeal and check for any other PTAB filings against this patent.

Now let me verify the panel composition, the exact claim-level outcome, and whether any other petitioner filed against this patent.

PTAB Proceedings — US 9,404,127 ("Non-liposomal systems for nucleic acid delivery")

Proceedings overview

One AIA trial proceeding is on file: IPR2018-00680, which went all the way through a Final Written Decision holding all 22 claims unpatentable, and was affirmed by the Federal Circuit — so the count is 1 total, 0 active, 1 with claims invalidated, 0 surviving claims, 0 settlements, 0 institution denials. The defensive posture this gives a defendant is close to absolute: every claim of US 9,404,127 has been canceled by the Board and that cancellation is final, so any demand letter or infringement theory built on this patent — claim 1 or any dependent claim — is premised on dead claims.

⚠️ Source conflict to flag up front. The "PTAB proceedings on file" block states that the USPTO ODP API returns no AIA trial proceedings for this patent. That is incorrect as of today (2026-10-01). Public record unambiguously shows IPR2018-00680, filed 2018-02-21, FWD 2019-09-10, CAFC affirmed 2023-04-11. I have treated the proceeding below as real; the ODP ingest for this patent appears stale or keyed to the wrong record. Do not rely on the "no PTAB activity" default for this patent.

Separately, the Google Patents litigation block on this patent attributes the PTAB entry to "Unified Patents PTAB Data" and lists "Petitioner: Unified Patents PTAB Data." That is a data-licensing attribution, not a party — Unified Patents was not the petitioner. The petitioner was Moderna. No defensive aggregator is in this chain.

IPR2018-00680 — Moderna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc. (later Arbutus Biopharma Corporation)

• Type: Inter Partes Review
• Filed: 2018-02-21
• Status: Final Written Decision — all challenged claims unpatentable (Outcome: Unpatentable; termination/close 2019-09-10). Plain-English gloss: the patent is dead as a matter of law, subject only to the (now-exhausted) appeal.
• Judge panel: Administrative Patent Judges David C. McKone, Frederick C. Laney, and Karl D. Easthom. Oral hearing held 2019-06-06 (the Board heard this case back-to-back with IPR2018-00739, which challenged US 9,364,435, on a shared record).
• Parties: Petitioner — Moderna Therapeutics, Inc. Patent Owner of record at filing — Protiva Biotherapeutics, Inc.; the patent was reassigned to Arbutus Biopharma Corporation by merger on 2018-02-20, and the appellant on the CAFC docket was still styled Protiva. That is the same entity — do not read it as a second party.
• Petition grounds: Anticipation of claims 1–22 (all claims of the patent) under pre-AIA 35 U.S.C. § 102(e)(2), based on U.S. Patent No. 8,058,069 (the "'069 patent") and the references incorporated by reference into it — U.S. Patent Pub. No. 2007/0042031 ("'031 publication," direct dilution method), U.S. Patent Pub. No. 2004/0142025 ("'025 publication," stepwise dilution method), U.S. Patent Pub. No. 2006/0083780 ("'780 publication"), and U.S. Patent No. 5,885,613 ("'613 patent"). The Board treated the incorporated disclosures as part of the '069 patent's disclosure ("as if they were explicitly contained therein," citing Advanced Display Systems). No § 103 theory was reached; no § 112 theory.
  • Notably, the '069 patent and the '127 patent are commonly owned by Arbutus and share three of the same inventors. Patent Owner conceded the '069 patent was prior art under pre-AIA § 102(e)(2) and did not dispute the incorporations.
• Institution decision: Instituted 2018-09-12 on the § 102(e)(2) anticipation ground as to all challenged claims. The substantive dispute the Board framed was whether the claim 1(d) "Morphology Limitation" — "wherein at least about 95% of the particles in the plurality of particles have a non-lamellar morphology" — was inherently disclosed.
• Final Written Decision: issued 2019-09-10 (Moderna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc., No. IPR2018-00680, 2019 WL 12447121 (P.T.A.B. Sept. 10, 2019)). Verdict at claim level: all 22 challenged claims unpatentable; no claim was sustained. Independent claim 1 was found inherently anticipated — the non-lamellar morphology is a natural property necessarily resulting from making the disclosed formulations by the disclosed direct dilution method. The dependent claims (including the mRNA claim, the "fully encapsulated" claim, the three-dimensional-structure claim, and the lipid-percentage-range claims) fell with it, on a mix of express and inherent anticipation through the incorporated references. Patent Owner's experimental evidence of non-inherency was found unavailing, and the Board relied on Patent Owner's own expert's apparent concession that the '435 continuation would also disclose the Morphology Limitation.
  • On appeal the panel articulated the standard this way: "[a] limitation is inherent if it is the 'natural result flowing from' the prior art's explicit disclosure," and "[t]he legal test requires that the embodiment(s) must necessarily yield the limitation." It found the two patents' formulations and processes to be "the same or essentially the same," so that practicing the '069 disclosure would "naturally result in a composition having the claimed morphological property."
• Settlement / termination: None. The proceeding ran to a Final Written Decision. There was no adverse-judgment termination and no settlement.
• Motion to amend: I could not confirm any motion to amend in -00680. A motion to amend/opposition appears in the parallel '435 case (IPR2018-00739), not here — do not conflate the two. Treat this as unverified rather than as "no motion filed," and it is moot in any event given the affirmance.
• Appeal: Yes — appealed, and affirmed.
  • Docket: CAFC No. 2020-1183, Arbutus Biopharma Corporation (fka Protiva Biotherapeutics, Inc.) v. ModernaTX, Inc. (fka Moderna Therapeutics, Inc.); docketed 2019-11-27; oral argument 2022-11-04; decided 2023-04-11.
  • Panel: Circuit Judges Reyna, Schall, and Chen. Precedential — reported at Arbutus Biopharma Corp. v. ModernaTX, Inc., 65 F.4th 656 (Fed. Cir. 2023).
  • Issues on appeal: (1) whether the Board erred in finding the Morphology Limitation inherently anticipated; (2) whether the incorporated references were properly treated as part of the '069 patent's disclosure for the dependent claims; (3) the contours of inherency under Schering, Hospira, Bristol-Myers, and Atlas Powder.
  • Disposition: AFFIRMED (Fed. Cir. Apr. 11, 2023; judgment entered same day: "ORDERED AND ADJUDGED: AFFIRMED"). The court held substantial evidence supported inherency, and that the incorporated references are "effectively part of the [host document] as if [they] were explicitly contained therein," so the dependent claims were anticipated as well.
  • Constitutional challenge: the CAFC docket reflects a Notice of Constitutional Challenge to Federal Statute filed with the appeal (2019-11-27) — consistent with an Appointments Clause / Arthrex challenge, which was live when the appeal was docketed. The precedential opinion as reported decides the case on the inherency merits; I could not confirm any separate ruling on the constitutional theory. Do not represent it as decided.
• Defensive value: Claim 1 and every dependent claim of US 9,404,127 are canceled and the cancellation is final. A demand letter citing this patent is citing a patent with no enforceable claims. This is the strongest possible IPR record for a defendant — but it only defeats theories built on this patent number; Arbutus's live assertions in this family rest on sibling/comparison patents that survived (see below).

Strategic summary

Canceled vs. sustained vs. untested. Every claim of US 9,404,127 — claims 1–22, as the FWD and the Federal Circuit both state — was held unpatentable. There are no surviving claims of this patent. There is no partial-win carve-out to argue around, no dependent claim that escaped, and no claim the Board declined to reach. The patent was not narrowed through amendment; it was invalidated root and branch for § 102 anticipation. If your adversary's chart maps your product onto claims 1–22 of the '127 patent, the chart is moot. (Live status check recommended: Google Patents shows this patent as "Expired – Fee Related" while also listing an anticipated expiration of 2031-06-30 and a terminal disclaimer over US 9,006,417. That status field is inconsistent with a patent whose claims were canceled on 2023-04-11, and it should be verified against USPTO PatentCenter rather than relied on.)

Estoppel landscape. Under § 315(e)(2), Moderna (and its real parties in interest and privies) is estopped in the district court from asserting any ground it raised or reasonably could have raised in IPR2018-00680 — which, on this record, sweeps in the '069 patent and the '031, '025, '780, and '613 references as anticipation art against the '127 patent. That estoppel, however, is party-specific. A different defendant is not estopped and remains free to run new § 102 or § 103 combinations against the patent. The practical point: there is almost nothing left to invalidate, and the useful prior art — the '069 patent and its family, and the Arbutus/Protiva publications and patents on LNP formulation and dilution processes — is now public, judicially blessed, and precedentially construed, including a precedential holding on inherency of particle morphology. That body of art is far more valuable as a defense against sibling Arbutus patents than against this one.

Pattern signals. The pattern here is a coordinated multi-patent, multi-front attack by a single petitioner. Moderna challenged three Arbutus LNP patents in sequence beginning 2018-02: the '127 patent (IPR2018-00680), the '435 patent (IPR2018-00739, heard on a shared record and a shared consolidated oral hearing on 2019-06-06), and the '069 patent. Outcomes diverged sharply — the '127 patent was wholly invalidated, the '435 patent was partially invalidated (survived only in narrowed form), and the '069 patent survived. Arbutus litigated hard rather than settling: it filed motion-to-strike and sanctions threats over the sur-reply and marked-up exhibits during the parallel -00739/-00680 prosecution, appealed the '127 FWD, and argued inherency on the merits at the Federal Circuit. The litigation posture is the tell: when Arbutus sued Moderna over Spikevax in the District of Delaware in February 2022 (1:22-cv-00252) and sued Pfizer/BioNTech in April 2023, it conspicuously did not assert the '127 patent — by then its claims were canceled on appeal. There is no defensive aggregator (e.g., Unified Patents) anywhere in this chain; the challenge was commercially motivated, not crowd-sourced. Related CAFC activity in the patent family includes the appeal of the '435 decision (Patent Owner prevailed in part), which is a different patent and should not be folded into the '127 analysis.

Recommended next steps

1. If a demand letter or complaint cites US 9,404,127, treat that as a red flag about the sender. Quote the disposition back: the FWD of 2019-09-10 found all of claims 1–22 unpatentable, and the Federal Circuit AFFIRMED on 2023-04-11 in No. 2020-1183. Link the operative documents:

   • CAFC opinion (precedential, 65 F.4th 656): https://cafc.uscourts.gov/opinions-orders/20-1183.OPINION.4-11-2023_2108936.pdf
   • Same opinion on CourtListener: https://www.courtlistener.com/opinion/[9390638](/patent/9390638)/arbutus-biopharma-corporation-v-modernatx-inc/
   • Appeal decision PDF (archived): https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/12/PTAB-IPR2018-00680-Appeal-Decision.pdf
   • Proceeding docket/status: https://ptacts.uspto.gov/ptab/caselist (search IPR2018-00680); third-party mirror with docket entries: https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2018-00680
     Assert that the patent has no enforceable claims and ask the sender to identify which patent it is actually asserting. In this family the realistic candidates are the '069 patent (fully sustained through IPR and CAFC), the '435 patent (sustained only as narrowed), and the other LNP composition patents Arbutus asserted in D. Del. against Moderna (1:22-cv-00252) and against Pfizer/BioNTech (D.N.J., April 2023) — the '127 patent is not among them.

2. If you are a defendant on a sibling patent, mine this record — but respect the estoppel line. The claim construction, incorporation-by-reference analysis, and precedential inherency law from this appeal are portable to the sibling Arbutus LNP patents, and the '127 prosecution history and exhibits (the '031/'025/'780/'613 references, the DDM/SDM process disclosures, the 1:57 / 1:62 / 2:40 / 2:30 / 10:15 formulations) are now thoroughly vetted. The '069 patent is the priority-document trap worth a fresh look from a non-Moderna defendant: it was found to be § 102(e)(2) prior art to the '127 patent, which cuts both ways depending on which patent you are facing.

3. No active proceedings to track. There is no pending IPR/PGR/CBM on US 9,404,127 and no live trial-stage calendar — no institution deadline, no hearing, no FWD due date. The statutory 1-year trial clock is irrelevant here. The only live question is administrative cleanup: whether the PTAB certificate of cancellation has been issued and how the patent's status field is reflected in PatentCenter (given the inconsistent "Expired – Fee Related" designation on Google Patents). If you need the paper trail, pull the FWD and the rehearing/certificate documents from the PTAB E2E case for IPR2018-00680.

4. Treat the upstream data source as unreliable for this patent. The ODP block's "no AIA trial proceedings" default is factually wrong here, and the Google Patents litigation block mislabels the data vendor as the petitioner. If your workflow keys off either signal for go/no-go on this patent, fix the feed before it drives a filing decision.

I'll verify the ownership chain against public records before reconstructing it.

Key finding already: the PTAB case was filed by Moderna, not an NPE. Let me verify the assignment records and corporate history.

Now let me verify the litigation/validity endgame and check for any security interests or licensing-only transfers.

US 9404127 — Ownership & Assignment Reconstruction

Verification limitation (read first). The USPTO Assignment Center query interface was not directly reachable with the tools available to me. Everything below is grounded in (i) the Google Patents legal-events record for US9404127B2 (which is populated from USPTO assignment data), (ii) a USPTO PTAB filing that states the corporate history under oath, and (iii) Arbutus/SEC corporate filings. Reel/frame numbers are exposed for only one link in this chain (039238/0654). I have not invented any others. To complete the reel/frame table, query assignmentcenter.uspto.gov or the legacy assignment.uspto.gov/patent/index.html by patent number 9404127.

Inventors

Notes / unusual patterns:

• All three are named as assignors on the 2016-06-03 / 2016-07-23 inventor assignments to Protiva Biotherapeutics, Inc., which is the ordinary employee-invention assignment pattern, not a transfer of ownership between companies.
• At the 2010-06-30 priority date, Protiva was already a wholly owned subsidiary of Tekmira Pharmaceuticals Corporation (business combination completed 2008-06-01). At the 2015-03-09 filing date of application 14/642,452, Tekmira had been renamed Arbutus Biopharma Corporation (March 2015).
• No "inventor exodus" signal. I found no evidence any of the three left Protiva/Tekmira/Arbutus within 12 months of filing. Do not read the 2018 amalgamation as a departure signal — it occurred ~8 years after the 2010 priority filing and is a corporate-law event, not a personnel one.

Original assignee

Protiva Biotherapeutics Inc. (British Columbia, Canada) — named as applicant/owner on the issued patent, with Arbutus Biopharma Corporation shown as current assignee.

• Primary business: lipid-nanoparticle / SNALP (stable nucleic acid-lipid particle) delivery technology for RNAi therapeutics; internal candidates were ApoB SNALP (hypercholesterolemia) and PLK-1 SNALP (oncology). Protiva was founded in summer 2000 by Dr. Mark J. Murray and spun out of Inex Pharmaceuticals.
• Did they ship a product embodying the claims? No marketed product was sold by Protiva or Arbutus embodying these claims. The SNALP/LNP platform was monetized by out-licensing (Alnylam, Roche, Merck, Dicerna, Monsanto, Alexion, and later Genevant). The closest embodiment in commerce is Alnylam's Onpattro (patisiran), which practices Arbutus-era LNP technology under license — not a product of the assignee.
• Current status: operating company, not dissolved and not in bankruptcy. Chain of title: Protiva (wholly owned sub of Tekmira from 2008-06-01) → Tekmira renamed Arbutus Biopharma Corporation (Nasdaq: ABUS) on 2015-03-04 acquisition of OnCore/Arbutus Inc. → Protiva Biotherapeutics, Inc. amalgamated into Arbutus Biopharma Corporation in January 2018 (per Arbutus's mandatory notices in IPR2018-00739). Arbutus is a clinical-stage biopharma (AB-729, AB-101) that underwent severe restructuring in 2024–25 (workforce cut ~40%, then a further ~57%, to 19 employees; exit of Warminster HQ; discontinued in-house research) but has not filed for bankruptcy protection.

Assignment timeline

Reel/frame is shown where the record exposes it. Where it is blank, the event is documented in the Google Patents legal-events record but the reel/frame was not retrievable with my tools — it is omitted, not invented.

• 2016-06-03 (executed) / recorded 2016-06-03 — Reel not retrieved

  • Conveyance: Assignment of assignors' interest
  • Assignor: Jeffs, Lloyd B.; Yaworski, Ed; Palmer, Lorne R.
  • Assignee: Protiva Biotherapeutics, Inc.
  • Correspondent: not exposed in the available record — cannot assess recurrence; flag as unresolved
  • Context: Administrative perfection of the pre-existing employee invention assignment to the applicant company, recorded around allowance/issue; not a change in beneficial ownership.

• 2016-07-23 (executed) / recorded 2016-07-23 — Reel 039238 / Frame 0654 (inferred: this is the "previously recorded" record referenced by the corrective assignment below)

  • Conveyance: Assignment of assignors' interest (re-recorded)
  • Assignor: Palmer, Lorne R.; Jeffs, Lloyd B.; Yaworski, Ed
  • Assignee: Protiva Biotherapeutics, Inc.
  • Correspondent: not exposed in the available record
  • Context: This is a duplicate/re-recorded inventor assignment — the same three assignors, same assignee, six weeks after the 2016-06-03 entry. Paperwork defect, not a transfer.

• 2016-08-19 (executed) / recorded 2016-08-19 — Reel not retrieved

  • Conveyance: Corrective Assignment — expressly "to correct the doc dates for assignor Lloyd B. Jeffs and Lorne R. Palmer previously recorded at Reel 039238, Frame 0654"
  • Assignor: Jeffs, Lloyd B.; Yaworski, Ed; Palmer, Lorne R.
  • Assignee: Protiva Biotherapeutics, Inc.
  • Correspondent: not exposed in the available record
  • Context: Correction of a recording error (document execution dates). Confirms the 2016-07-23 record is the operative one; still no change in ownership.

• 2018-01 (executed — amalgamation) / recorded 2018-02-20 — Reel not retrieved

  • Conveyance: Merger
  • Assignor: Protiva Biotherapeutics Inc.
  • Assignee: Arbutus Biopharma Corporation
  • Correspondent: not exposed in the available record
  • Context: Internal reorg. Amalgamation of a wholly owned subsidiary into its publicly traded parent; Arbutus had been the real party in interest since the 2015 Tekmira→Arbutus name change.

Nothing further is recorded after 2018-02-20. No security agreement, no license recorded as an assignment, no transfer to a licensing entity, no defensive aggregator. Note also that the 2018-04-11 Cross License Agreement with Genevant Sciences Ltd. is a license, not an assignment — the patents remained owned by Arbutus (Acuitas's SDNY complaint describes the nine patents as "owned by Arbutus and licensed to Genevant").

Timeline diagram

timeline
    title Ownership of US 9404127
    2000 : Protiva Biotherapeutics founded in Vancouver
    2008 : Tekmira acquires Protiva
    2010 : Priority application filed by Protiva
    2015 : Continuation application filed
    2016 : Inventors assign rights to Protiva
         : Patent US 9404127 issues
         : Corrective assignment recorded
    2018 : Protiva amalgamated into Arbutus Biopharma
         : Moderna files IPR against the 127 patent
    2019 : PTAB invalidates all claims
    2022 : Acuitas names 127 patent in DJ suit
    2023 : CAFC affirms invalidity

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The only post-inventor transfer is Protiva Biotherapeutics Inc. → Arbutus Biopharma Corporation via Merger, recorded 2018-02-20. Protiva was a wholly owned subsidiary of the assignee (per Arbutus's List of Subsidiaries: Protiva, BC Canada, wholly owned since May 30, 2008) and was amalgamated into the parent in January 2018. There is no "IP / Holdings / Ventures / Licensing" entity anywhere in the chain, no registered-agent address, and no single-purpose LLC. Arbutus is a Nasdaq-listed operating biopharma.

2. Known asserter in the chain — NOT PRESENT.
Assignees of record are Protiva Biotherapeutics Inc., Tekmira Pharmaceuticals Corporation, and Arbutus Biopharma Corporation. None appears on the Acacia / Marathon / Intellectual Ventures / IPNav / Wi-LAN / Conversant-Mosaid / Vringo / Pendrell / Innovatio / MPHJ / Lumen View / Round Rock / Document Generation lists, or on Unified Patents' or RPX's high-frequency-plaintiff directories.
⚠️ Do not misread the Google Patents litigation banner. It labels the PTAB case "Unified Patents PTAB Data" — that is the data provider for the banner, not the petitioner. The actual petitioner in IPR2018-00680 (filed 2018-02-21) was Moderna Therapeutics, Inc., a competitor. Likewise, the Delaware case 1:22-cv-00252 (Arbutus v. Moderna, filed 2022-02-28) and S.D.N.Y. 1:22-cv-02229 (Acuitas v. Genevant/Arbutus, filed 2022-03-18) are competitor/declaratory-judgment actions, not NPE suits.

3. Repeat correspondent across the chain — UNCLEAR (data not retrievable).
This is the one signal I genuinely cannot score. Google Patents legal events for this patent do not expose correspondent names or addresses, and I could not reach the Assignment Center to read them. The recording activity here — two inventor assignments plus a corrective, all within 11 weeks of each other in 2016 — is the kind of clustering worth checking for a single repeat filer. Action item: pull reels 039238/0654 and the 2016-06-03 and 2016-08-19 records and read the correspondent field; also cross-check that correspondent against the Arbutus/Protiva family (US9006417, US9518272, US11718852, US9364435, US8058069) to see whether one firm handled the entire LNP portfolio.

4. Cascading transfers — NOT PRESENT.
Two substantive ownership events across 8 years (2016 inventor assignment; 2018 merger), separated by ~19 months, both intra-group. No chained LLCs, no shared correspondent addresses, no common-principal pattern. The 2016 cluster is a paperwork correction, not a cascade.

5. Pre-litigation transfer — NOT PRESENT.
No assignment falls within 6 months before any suit naming this patent. The last ownership event is 2018-02-20; the first action naming the '127 patent is Acuitas's DJ complaint of 2022-03-18 (~49 months later), and Arbutus's own infringement suit (D. Del. 1:22-cv-00252, 2022-02-28) does not assert the '127 patent at all. Curiosity worth noting: the merger assignment was recorded 2018-02-20, one day before Moderna filed IPR2018-00680 on 2018-02-21 — a coincidence of the amalgamation certificate date, not evidence of assertion-driven structuring (Arbutus had been the real party in interest since 2015).

6. Bankruptcy fire-sale — NOT PRESENT (for this patent).
No sale of US9404127 out of any insolvency proceeding. The upstream Inex Pharmaceuticals insolvency and asset transfer to Tekmira predates this patent's 2010-06-30 priority and did not involve this application. Arbutus's 2024–25 restructuring (~40% + ~57% workforce reductions, exit of Warminster HQ) is a cost-cutting event, not a Chapter 7/11 proceeding.

7. Privateering — NOT PRESENT (with one adjacent structure to watch).
The defining element — transfer of ownership to an NPE that asserts on the operating company's behalf — is absent; ownership never left the operating company. The adjacent structure is the Genevant Sciences relationship: Arbutus cross-licensed its LNP IP to Genevant (a Roivant joint venture) by agreement dated 2018-04-11, and Arbutus and Genevant co-filed the Moderna and Pfizer/BioNTech suits. Acuitas's pleadings confirm the patents remained "owned by Arbutus and licensed to Genevant." That is a JV co-assertion vehicle, not a shell transfer — but it is the piece of this story that most resembles a licensing-enforcement construct.

8. Defensive aggregator — NOT PRESENT.
The chain terminates at Arbutus Biopharma Corporation, an operating company that asserts the family offensively. No RPX / AST / LOT / Unified / OIN link anywhere.

Material additional fact — the asset has been neutralized by invalidation, not by aggregation. In IPR2018-00680 (petitioner Moderna, filed 2018-02-21), the PTAB held all claims of US9404127 invalid on 2019-09-10 on anticipatory prior art, and the Federal Circuit affirmed (appeal 20-1183; reported 2023-04-11). Google Patents shows the patent's status as "Expired – Fee Related" with anticipated expiration 2031-06-30 (terminal disclaimer over US9006417). Arbutus deliberately did not assert the '127 patent in its 2022 Moderna suit, relying instead on US9364435, US8058069, US8492359, US8822668, US11141378 and US9504651.

Verdict

Operating-company assertion.

The chain runs inventors → Protiva Biotherapeutics Inc. (2016 inventor assignments, incl. the operative record at Reel 039238/Frame 0654 and the 2016-08-19 corrective assignment) → Arbutus Biopharma Corporation by intra-group merger recorded 2018-02-20. There is no shell LLC, no registrant-agent address, no NPE on the assignee side, and no defensive aggregator; the family was asserted by the operating company against genuine competitors — Moderna (IPR2018-00680, and D. Del. 1:22-cv-00252) and Pfizer/BioNTech (D.N.J. 2:23-cv-01876) — with Genevant as licensed co-plaintiff.

The one caveat that keeps this from being a clean textbook case is that Arbutus ships no product embodying the claims — it is a clinical-stage, licensing-driven biopharma whose 2024–25 downsizing left 19 employees — so the assertion is monetization-of-R&D rather than classic competitor-versus-competitor product litigation. Even so, the evidence points away from NPE status: 7 of 8 signals are not present, the only genuine gap is correspondent recurrence (signal 3, unretrievable), and the patent itself was invalidated and is now expired for fee non-payment, so it carries no live assertion value.

Verify at: USPTO Assignment Center — search "9404127" · legacy Assignment Search — specifically request reels 039238/0654 (2016-07-23), the 2016-06-03 and 2016-08-19 records, and the 2018-02-20 merger record, and capture the correspondent of record on each.

I'll research US patent 9404127 and its cited prior art references.

Let me get the specific prior art citations listed on the patent.

Let me search for the IPR proceedings and the specific cited references, which are key to the prior art analysis.

I was able to retrieve the patent's bibliographic data and its litigation/PTAB history, but I hit a tool-step limit before I could pull the complete "References Cited" list off the face of the patent. I'll give you everything I can verify, flag precisely what I could not verify, and explain the § 102 framework — rather than inventing a citation list, which would be the worst possible failure mode here.

1. Patent identification (interpreted literally)

Family: US 9,404,127 B2; US 9,006,417 B2; US 9,518,272 B2; US 11,718,852 B2; US 2017/0260523 A1; US 2019/0032051 A1; WO 2012/000104 A1; provisional 61/360,480.

Claim 1 (independent, per the family record): A composition comprising a plurality of nucleic acid‑lipid particles, each comprising (a) a nucleic acid; (b) a cationic lipid; (c) a non‑cationic lipid; and (d) a conjugated lipid that inhibits aggregation of particles, wherein at least about 95% of the particles have a non‑lamellar morphology.

Note on the two conflicting legal-status signals in my sources: Google Patents' own banner and the Korean KHIDI analysis show "Expired – Fee Related / registered," while the litigation literature states the patent was invalidated. Both can be true simultaneously (invalidity holding pending/affirmed ≠ removal of expiry status). I flag this rather than resolve it.

2. Critical procedural fact you should fold into any § 102 analysis

This patent was not invalidated by the examiner's cited art. It was invalidated in an AIA post-grant proceeding:

• IPR2018‑00680, Petitioner listed as Unified Patents in Google Patents' PTAB data (contemporaneous reporting attributes the challenge campaign to Moderna, filed against the '127 in Feb 2018). Google Patents marks it "PTAB case IPR2018-00680 filed (Final Written Decision) – Critical."
• Reported outcome: all claims held unpatentable at the PTAB, and the Federal Circuit affirmed on April 11, 2023.
• Related co-pending family/LNP litigation: New York S.D.N.Y. 1:22‑cv‑02229 (Acuitas v. Genevant/Arbutus) and D. Del. 1:22‑cv‑00252; CAFC 20‑1183.

Implication: For US 9,404,127, the legally operative prior art is the IPR2018‑00680 grounds, not the patents listed under "References Cited" on the cover page. The cover-page citations are overwhelmingly background art (foundational liposome/encapsulation patents), which is exactly why they didn't kill the claims but the IPR art did. I could not retrieve the IPR's specific grounds/reference list in this session.

3. Prior-art references I can actually confirm for US 9,404,127

The full patent text I was given is truncated before the "(56) References Cited" block. From the patent's own front page (as reproduced in the Acuitas v. Genevant complaint PDF, Docket Alarm), the U.S. Patent Documents list begins:

I am confident of the reference numbers, dates, and first-listed inventors because they appear in the patent's own front-page continuation. I am hedging the exact titles because I could not re-verify them in this session.

Why none of these anticipate: pre-AIA § 102 anticipation requires a single reference disclosing every limitation of the claim as arranged. The distinctive limitation here is the "at least about 95% non‑lamellar morphology" of a cationic-lipid/non-cationic-lipid/conjugated-lipid nucleic-acid particle. The 1983–1985 liposome art teaches the opposite structural paradigm (closed bilayer vesicles). None of these three references, on their own, discloses the non‑lamellar (inverted hexagonal HII or cubic) morphology limitation. They are thus, at most, § 103 combination fodder — not § 102 anticipatory art.

Other listed items I can see referenced in the patent prose (these are background, cited in the specification, not necessarily in the (56) block): U.S. Pat. No. 6,458,382; U.S. Pat. No. 6,429,200 (reverse micelles); U.S. Pub. Nos. 20030073640, 20030026831, 20020081736, 20030082103; and incorporated-by-reference Pub. Nos. 20040142025, 20070042031, 20060240554, WO 00/03683, WO 2004/078941, WO 2010/006282.

4. Do NOT treat these as prior art (common trap)

Several items that surface near this patent in databases are same-family members, not prior art:

• US 9,006,417 B2 — the parent of the '127 (same inventors/applicant). A family member is not § 102 prior art against its own continuation, and the '127 carries a terminal disclaimer to it.
• WO 2012/000104 A1 — the PCT publication of the same application.
• US 9,518,272 B2, US 2017/0260523 A1, US 2019/0032051 A1, US 11,718,852 B2 — later continuations/divisionals in the same chain.

Also be careful with a false-positive I encountered: a "References Cited" snippet beginning "FR 2744010 A1… GB 401677 A 11/1933…" belongs to US 11,185,320 (an unrelated mechanical patent), not to US 9,404,127. Do not attribute those foreign references to the '127.

5. Statutory framework and effective date

• Because the earliest priority is June 30, 2010, the '127 is a pre‑AIA patent. The governing provision is pre-AIA 35 U.S.C. § 102 (subsections (a), (b), (e)), with § 103 obviousness as the fallback. Prior art must predate the June 30, 2010 priority date (or, for subject matter only supported by the June 30, 2011 PCT filing, that later date).
• For § 102 anticipation of claim 1, a single reference must disclose the nucleic acid, the cationic lipid, the non-cationic lipid, the anti-aggregation conjugated lipid, and the ≥95% non-lamellar morphology.

6. What I could not do, and how to close the gap

I must be explicit: I did not obtain the complete "(56) References Cited" list for US 9,404,127 in this session. I therefore cannot responsibly give you a per-reference, per-claim § 102 map for the full citation set, and I will not fabricate one. The user's own full-text extract (provided in the prompt) is truncated at the specification and never reaches the citation block.

To produce the complete, defensible analysis you asked for, pull these three primary sources directly:

1. USPTO PatentCenter / Patent Full-Text for 14/642,452 — the complete "(56) References Cited" U.S. and foreign patent documents, plus the prosecution file wrapper (examiner's § 102/§ 103 rejections identify the actually-applied art).
2. USPTO PTAB, IPR2018‑00680 — the Petition's Grounds and Exhibits (the references at Ex‑1001, Ex‑1002, etc.) and the Final Written Decision. This is the art that actually invalidated the claims, and it is far more probative than the cover-page citations.
3. Google Patents US9404127B2 → "Cited By" and "References Cited" tabs (URL: https://patents.google.com/patent/US9404127/en).

Once you have the IPR exhibit list, the § 102 analysis becomes tractable — and my strong expectation is that the anticipation/obviousness theory rests on the non-lamellar morphology limitation combined with the specific SNALP lipid ratios described in the specification, not on the 1980s liposome patents.

Bottom line: The references I can confirm on the face of US 9,404,127 (e.g., US 4,394,448, US 4,438,052, US 4,515,736) are foundational lamellar liposome/encapsulation art and do not anticipate any claim, because they lack the "≥95% non-lamellar morphology" limitation that defines the invention. The art that actually defeated the patent came from IPR2018‑00680, which I identified but whose specific reference list I could not retrieve within my search budget.

I'll research the prior art cited in this patent and the related PTAB proceedings to ground the obviousness analysis.

Let me gather more detail on the specific prior art references and the grounds asserted.

Let me get the specific grounds asserted in the petition and the Federal Circuit's framing.

Preliminary caveats

Before the analysis, three points that materially shape it:

1. This patent has already been litigated to judgment. US 9,404,127 was the subject of IPR2018-00680 (Moderna Therapeutics v. Protiva Biotherapeutics). The Board's Final Written Decision (Sept. 10, 2019) held claims 1–22 unpatentable — on anticipation under § 102, not § 103 — and the Federal Circuit affirmed on April 11, 2023 in Arbutus Biopharma Corp. v. ModernaTX, Inc., No. 2020-1183. So a § 103 analysis below is reconstructive, not the operative holding.
2. Pre-AIA § 103(a) governs. Priority date per Google Patents is 2010-06-30 (provisional 61/360,480). The Board and the Federal Circuit applied pre-AIA § 102(e)(2) and § 102(a).
3. I could not retrieve the verbatim text of "Grounds 1–4" of the petition (the Janoff declaration states Grounds 1–4 "disclose[] or render[] obvious" the claims, per ptacts.uspto.gov). I therefore frame combinations from the exhibits and prior-art discussion in the Petition's Section VIII ("PRIOR ART") and the Board's decisions, and flag where I am inferring.

1. The claim at issue

Claim 1 (col. 149:29–37) is a composition claim:

A composition comprising: a plurality of nucleic acid-lipid particles, wherein each particle comprises: (a) a nucleic acid; (b) a cationic lipid; (c) a non-cationic lipid; and (d) a conjugated lipid that inhibits aggregation of particles, wherein at least about 95% of the particles in the plurality of particles have a non-lamellar morphology.

Dependent claims add (i) the 50–85 mol% cationic / 13–49.5 mol% non-cationic / 0.5–10 mol% conjugated ranges; (ii) narrower sub-ranges (e.g., 56.5–66.5, 52–62, 50–60 mol% cationic); (iii) species selections (DLinDMA, DLin-K-C2-DMA/"XTC2", cholesterol, DSPC, PEG-C-DMA); (iv) siRNA/mRNA/fully-encapsulated nucleic acid; and (v) inverse hexagonal (HII) or cubic three-dimensional structures.

The only element not expressly in the prior art is the quantitative morphology limitation ("at least about 95% non-lamellar"). Everything else is a formulation that was squarely disclosed.

2. The prior art of record (Petition § VIII and its exhibit list)

3. § 103 combinations

Combination A — the '069 patent, alone or with its incorporated '031 publication (single-reference / near-identity obviousness)

This is the strongest ground, and it is the one that actually succeeded (as anticipation).

Where every element sits: The '069 patent discloses a plurality of nucleic acid-lipid particles comprising a nucleic acid, a cationic lipid, a non-cationic lipid, and a PEG-lipid (Ex. 1002, 3:27–45); it names the 1:57 and 1:62 formulations as "preferred embodiment[s]" (Ex. 1002, 3:43–56); and it states SNALP "can be formed by any method known in the art including … a direct dilution process," incorporating the '031 publication "in its entirety" (Ex. 1002, 57:50–55, 59:12–16). The 1:62 formulation studied in the '127 patent (62.0 mol% DLinDMA) and in the '069 patent (61.5 mol%) differ by 0.5 mol% — the Board credited Dr. Janoff that no change in three-dimensional structure would be expected (FWD, citing Ex. 1024, 326:7–19).

Motivation to combine (or to "arrive at"): Even setting aside inherency, a POSITA reading the '069 patent would have been expressly directed to (i) the 1:57 and 1:62 lipid ratios as preferred and (ii) DDM as the production route. Where the reference itself identifies the target formulation and the target process, the "motivation" prong is satisfied by the reference's own teaching. The only remaining variable — particle morphology — is a result-effective property of the composition-plus-process, which the '127 patent itself concedes ("the physical property or morphology … depends on two factors: (1) the lipids used for making the formulations and (2) the process used to form the particles"). An applicant cannot obtain a patent on a newly discovered property of a known composition made by a known process. Bristol-Myers Squibb v. Ben Venue, 246 F.3d 1368 (Fed. Cir. 2001).

Risk: This is really a § 102 argument wearing a § 103 hat. If the morphology limitation is treated as a separate, non-inherent limitation (which the Board refused to do), then a § 103 case requires an articulated reason to select for ≥95% non-lamellar particles — and the '069 patent is admittedly silent on that percentage.

Combination B — the '565 patent (or '027) + the '658 patent + the '031 publication

Teachings: '565 discloses SNALP built from DLinDMA/DSPC/cholesterol/PEG-C-DMA at the 2:30 ratio, encapsulating siRNA against ApoB — the same target the '127 patent uses. '658 discloses 2:30 and 2:40 and recites a direct dilution process. The '031 publication supplies the DDM apparatus and parameters.

Motivation: (a) Common ownership and mutual cross-reference — these are all Protiva/Tekmira-family filings; '565 and '658 are expressly cited within one another, so the combination is not hindsight-driven. (b) Known problem, known solution — '565's own Examples 16, 17 and 20 systematically vary PEG-C-DMA from 1 to 15 mol% and cationic lipid across 15/20/30 mol% and measure plasma clearance, biodistribution, and silencing (see US 9,181,545 and the '565 family disclosure). Optimizing a mol% of a formulation component along a disclosed gradient is the paradigm of routine optimization of a result-effective variable (In re Applied Materials, 692 F.3d 1289). (c) Process selection — a POSITA scaling SNALP manufacture would select DDM because the '658 patent and the '127 patent itself both point to it.

Risk: The Federal Circuit's Dec. 1, 2021 decision in ModernaTX, Inc. v. Arbutus Biopharma Corp., No. 2020-2329, affirmed the Board's holding that the '069 patent was nonobvious over just this kind of art. The court emphasized that Arbutus showed "the properties of nucleic acid-lipid particles depend on the particle as a whole, rather than on any one component," that the presumption of obviousness for overlapping ranges did not apply because "the possibility of calculating multiple different ranges … cuts against" it, and that Moderna failed to "address the interdependence of the claimed lipid components." See Winston & Strawn summary. That reasoning applies with force here: the four lipid components are interdependent, so "combine '565 + '658 + '031" may not be legally sufficient absent evidence that the resulting particles are viable and predominantly non-lamellar.

Combination C — the '069 patent (or '565) + the '099 patent (morphology motivation)

Teaching: The '099 patent discloses lipid formulations designed to transition to an inverted hexagonal (non-lamellar) structure, and states that "the inverted hexagonal structure transfers mammalian cells more efficiently than the lamellar structure" (Institution Decision, quoting Ex. 1004, 5:52–54, 33:38–46).

Motivation: This supplies the missing reason to want a predominantly non-lamellar population: the art expressly taught that the non-lamellar phase is the more transfection-competent one. A POSITA seeking to improve silencing potency of an already-disclosed SNALP formulation would have been motivated to select lipid ratios/processes that favor that phase.

Risk (this is where the ground fails): The Board expressly rejected this rationale at institution, holding that the petitioner's statements about what "a POSITA would appreciate" and "would have been obvious" were "conclusory" and insufficient, and — critically — that the petitioner "never explains whether a person of ordinary skill in the art would have had a reasonable expectation of success in achieving the claimed invention." See Institution Decision. Also, the '099 patent's non-lamellar phase is pH-triggered (5.5–6.5), i.e., induced during endosomal transit, not the ambient morphology of the as-formulated particle that claim 1 requires.

Combination D — the district-court-style formulation-art combination

In the parallel litigation, invalidity contentions pleaded § 103 over MacLachlan WO 2005/007196, US 2006/0134189, Lin et al., 84 Biophys. J. 3307 (2003) (membrane charge density controls transfection in lamellar cationic-liposome-DNA complexes), and Chen et al., US 2006/0240554 (see Acuitas v. Genevant complaint extract). Lin et al. is the interesting one: it is a mechanistic teaching about how lipid packing/charge density governs transfection, which a petitioner would use to argue that manipulating lipid ratios to alter phase behavior was a predictable exercise. Standing alone, this group is the weakest — it is general LNP formulation art with no focus on the 1:57/1:62 ratios or on ≥95% non-lamellar populations.

4. Motivation-to-combine summary and expectation of success

A petitioner's best articulation is:

1. Same field, same problem, same components. All references address systemic siRNA delivery via PEGylated cationic-lipid nanoparticles; the component classes (cationic lipid / non-cationic lipid / PEG-lipid / nucleic acid) are identical.
2. The references direct the combination themselves. '565 → '658 → '069 are related filings that cross-reference each other and the '031/'025 publications.
3. Result-effective variable + routine optimization. Cationic-lipid and PEG-lipid mol% had already been titrated across a disclosed working range with in vivo silencing readouts.
4. Predictable solution to a known problem — KSR, 550 U.S. 398, 417, 421.

But the expectation-of-success prong is the vulnerability, and Arbutus's own PTAB submissions supply the counter-evidence: "The effects of making changes to the proportion of other components in the lipid particle would be unpredictable. Such changes, even if apparently minor in nature, would not be expected to produce a functional lipid particle suitable for systemic use." (Patent Owner Response at 18, in IPR2018-00739, quoted in the Acuitas complaint.) In re Stepan Co., 868 F.3d 1342 (Fed. Cir. 2017) and the Board's institution decision both treat the absence of a reasonable-expectation showing as fatal to a conclusory § 103 case.

5. Bottom line

• The legally operative result is anticipation, not obviousness. The Board found claims 1–22 anticipated by the '069 patent because the claimed non-lamellar morphology is the inherent "natural result flowing from" the prior art's express disclosure of the same lipid compositions processed by the same DDM; the Federal Circuit affirmed (Apr. 11, 2023). See FWD; Illinois Lawyer Now summary. Anticipation is the narrower case — a reference that anticipates necessarily renders the claim obvious.
• As a pure § 103 matter, the two viable theories are (A) the '069 patent + its incorporated '031 publication (essentially the appeal-winning ground restyled), and (B) '565 / '027 / '658 + '031 with routine optimization of lipid mol%. Ground (C), the '099 patent morphology motivation, is the cleanest legal rationale for the "non-lamellar" element but was rejected as conclusory and unsupported on expectation of success.
• The principal obstacle to any § 103 case is the Federal Circuit's nonobviousness holding on the sibling '069 patent (ModernaTX v. Arbutus, No. 2020-2329) and Arbutus's "interdependent result-effective variables" evidence, which directly attacks the predictability of changing any one lipid mol%.

Confidence note: I have high confidence in the prior-art identifications, the claim language, the FWD/institution-decision reasoning, and the Federal Circuit outcomes, all of which are corroborated across multiple sources. I have lower confidence in the precise composition of Petition "Grounds 1–4" — I could not retrieve that section verbatim, so § 3 above is a reconstruction from the exhibit list, the Board's characterization, and the Janoff declaration, not a quotation of the petition's grounds.